Cargando…

Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2

BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has sparked investigations to explore the clinical utility of its variants for guiding the development of new diagnostic and therapeutic strategies. However, interpreting the resulting associations into function still remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Eric W, Been, Latonya F, Lerner, Megan, Brackett, Daniel, Lightfoot, Stan, Bullen, Elizabeth C, Sanghera, Dharambir K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675375/
https://www.ncbi.nlm.nih.gov/pubmed/23617586
http://dx.doi.org/10.1186/1471-2156-14-28
_version_ 1782476079215149056
author Howard, Eric W
Been, Latonya F
Lerner, Megan
Brackett, Daniel
Lightfoot, Stan
Bullen, Elizabeth C
Sanghera, Dharambir K
author_facet Howard, Eric W
Been, Latonya F
Lerner, Megan
Brackett, Daniel
Lightfoot, Stan
Bullen, Elizabeth C
Sanghera, Dharambir K
author_sort Howard, Eric W
collection PubMed
description BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has sparked investigations to explore the clinical utility of its variants for guiding the development of new diagnostic and therapeutic strategies. However, interpreting the resulting associations into function still remains unclear. Canonical Wnt signaling regulates β-catenin and its binding with TCF7L2, which in turn is critical for the production of glucagon-like peptide-1 (GLP-1). This study examines the role of a novel frame-shift insertion discovered in a conserved region of WNT16a, and it is proposed that this mutation affects T2D susceptibility in conjunction with gene variants in TCF7L2. RESULTS: Our results predicted that the insertion would convert the upstream open reading frame in the Wnt16a mRNA to an alternative, in-frame translation initiation site, resulting in the prevention of nonsense-mediated decay, leading to a consequent stabilization of the mutated WNT16a message. To examine the role of Wnt16a in the Wnt signaling pathway, DNA and serum samples from 2,034 individuals (48% with T2D) from the Sikh Diabetes Study were used in this investigation. Prevalence of Wnt16a insertion did not differ among T2D cases (33%) and controls (32%). However, there was a 3.2 fold increase in Wnt16a mRNA levels in pancreatic tissues from the insertion carriers and a significant increase (70%, p < 0.0001) in luciferase activity in the constructs carrying the insertion. The expression of TCF7L2 mRNA in pancreas was also elevated (~23-fold) among the insertion carriers (p=0.003). CONCLUSIONS: Our results suggest synergistic effects of WNT16a insertion and the at-risk ‘T’ allele of TCF7L2 (rs7903146) for elevating the expression of TCF7L2 in human pancreas which may affect the regulation of downstream target genes involved in the development of T2D through Wnt/β-catenin/TCF7L2 signaling pathway. However, further studies would be needed to mechanistically link the two definitively.
format Online
Article
Text
id pubmed-3675375
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36753752013-06-08 Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2 Howard, Eric W Been, Latonya F Lerner, Megan Brackett, Daniel Lightfoot, Stan Bullen, Elizabeth C Sanghera, Dharambir K BMC Genet Research Article BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has sparked investigations to explore the clinical utility of its variants for guiding the development of new diagnostic and therapeutic strategies. However, interpreting the resulting associations into function still remains unclear. Canonical Wnt signaling regulates β-catenin and its binding with TCF7L2, which in turn is critical for the production of glucagon-like peptide-1 (GLP-1). This study examines the role of a novel frame-shift insertion discovered in a conserved region of WNT16a, and it is proposed that this mutation affects T2D susceptibility in conjunction with gene variants in TCF7L2. RESULTS: Our results predicted that the insertion would convert the upstream open reading frame in the Wnt16a mRNA to an alternative, in-frame translation initiation site, resulting in the prevention of nonsense-mediated decay, leading to a consequent stabilization of the mutated WNT16a message. To examine the role of Wnt16a in the Wnt signaling pathway, DNA and serum samples from 2,034 individuals (48% with T2D) from the Sikh Diabetes Study were used in this investigation. Prevalence of Wnt16a insertion did not differ among T2D cases (33%) and controls (32%). However, there was a 3.2 fold increase in Wnt16a mRNA levels in pancreatic tissues from the insertion carriers and a significant increase (70%, p < 0.0001) in luciferase activity in the constructs carrying the insertion. The expression of TCF7L2 mRNA in pancreas was also elevated (~23-fold) among the insertion carriers (p=0.003). CONCLUSIONS: Our results suggest synergistic effects of WNT16a insertion and the at-risk ‘T’ allele of TCF7L2 (rs7903146) for elevating the expression of TCF7L2 in human pancreas which may affect the regulation of downstream target genes involved in the development of T2D through Wnt/β-catenin/TCF7L2 signaling pathway. However, further studies would be needed to mechanistically link the two definitively. BioMed Central 2013-04-23 /pmc/articles/PMC3675375/ /pubmed/23617586 http://dx.doi.org/10.1186/1471-2156-14-28 Text en Copyright © 2013 Howard et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Howard, Eric W
Been, Latonya F
Lerner, Megan
Brackett, Daniel
Lightfoot, Stan
Bullen, Elizabeth C
Sanghera, Dharambir K
Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
title Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
title_full Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
title_fullStr Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
title_full_unstemmed Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
title_short Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
title_sort carriers of a novel frame-shift insertion in wnt16a possess elevated pancreatic expression of tcf7l2
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675375/
https://www.ncbi.nlm.nih.gov/pubmed/23617586
http://dx.doi.org/10.1186/1471-2156-14-28
work_keys_str_mv AT howardericw carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2
AT beenlatonyaf carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2
AT lernermegan carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2
AT brackettdaniel carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2
AT lightfootstan carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2
AT bullenelizabethc carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2
AT sangheradharambirk carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2